Sign in Subscribe

metastatic

A collection of 142 issues

Metastatic CRC Diagnosed Before Age 35 May Be a Distinct Subset

Skip to content The CRC Digest Metastatic CRC Diagnosed Before Age 35 May Be a Distinct Subset An Australasian registry study compared demographic and clinicopathologic characteristics of metastatic colorectal cancer patients diagnosed before age 35 with those diagnosed at 35–49 years and ≥50 years. (International Journal of Cancer) This

Vactosertib Plus Pembrolizumab Shows Manageable Safety in Non-MSI-High mCRC

Skip to content The CRC Digest ◆ TRIAL DATA Vactosertib Plus Pembrolizumab Shows Manageable Safety in Non-MSI-High mCRC A phase Ib/IIa study of vactosertib combined with pembrolizumab in non-MSI-high metastatic colorectal cancer demonstrated a manageable safety profile, with secondary outcomes including objective response rate, progression-free survival, and overall survival. (Nature

Cetuximab Rechallenge Tested Against Regorafenib in RAS Wild-Type mCRC

Skip to content The CRC Digest ◆ TRIAL DATA Cetuximab Rechallenge Tested Against Regorafenib in RAS Wild-Type mCRC A single-center randomized trial evaluated cetuximab plus irinotecan rechallenge versus regorafenib in RAS wild-type, microsatellite-stable metastatic colorectal cancer patients who had previously responded to then progressed off cetuximab, with progression-free survival as the

Dual KRAS Y96C/Y96S resistance mutations emerge after KRAS G12C inhibitor therapy

Skip to content The CRC Digest ◇ RESEARCH Dual KRAS Y96C/Y96S resistance mutations emerge after KRAS G12C inhibitor therapy Liquid biopsy detected concurrent Y96S and Y96C mutations in a patient with KRAS G12C-mutated metastatic CRC who progressed after 9.3 months of KRAS G12C inhibitor monotherapy; these polyclonal alterations were

First-line immunotherapy outperforms chemotherapy in MSI-H/dMMR metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA First-line immunotherapy outperforms chemotherapy in MSI-H/dMMR metastatic colorectal cancer A meta-analysis of phase III trials confirms immune checkpoint inhibitors show superior progression-free and overall survival compared to standard chemotherapy as first-line treatment for patients with MSI-H or dMMR metastatic disease. (J

CRC Research Update — July 20, 2026

Today's colorectal cancer research highlights

Circulating tumor DNA may identify which patients benefit from chemotherapy after liver metastasis surgery

Skip to content The CRC Digest ◆ TRIAL DATA Circulating tumor DNA may identify which patients benefit from chemotherapy after liver metastasis surgery The phase II GALAXY study (298 patients) found that ctDNA testing 2-10 weeks after surgery for colorectal liver metastases could help predict which patients are most likely to

Phase III trial finds no survival benefit from adding chemotherapy to surgery for peritoneal metastases

Skip to content The CRC Digest ◆ TRIAL DATA Phase III trial finds no survival benefit from adding chemotherapy to surgery for peritoneal metastases The CAIRO6 trial (351 patients) found that perioperative systemic therapy did not significantly improve overall survival compared to surgery alone in patients with resectable peritoneal-only metastases (44

CRC Research Update — July 19, 2026

Today's colorectal cancer research highlights

BREAKWATER trial compares encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA BREAKWATER trial compares encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer This randomized study evaluated targeted therapy combinations specifically for patients with BRAF V600E mutations, a subtype associated with poorer outcomes. (Annals of Oncology) This